Literature DB >> 1869282

Potential innovations in scheduling of cancer chemotherapy.

L Norton, R Day.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 1869282

Source DB:  PubMed          Journal:  Important Adv Oncol        ISSN： 0883-5896


× No keyword cloud information.
  5 in total

1.  Three dimensional staging of breast cancer.

Authors:  I L Wapnir; D E Wartenberg; R S Greco
Journal:  Breast Cancer Res Treat       Date:  1996       Impact factor: 4.872

2.  Phase II clinical trial with gemcitabine and paclitaxel sequential monotherapy as first-line treatment for advanced non-small-cell lung cancer (SLCG 01-04).

Authors:  Vega Iranzo; Rafael Sirera; Alfredo Carrato; Andrea Cabrera; Eloísa Jantus; Ricardo Guijarro; Elena Sanmartín; Ana Blasco; Mireia Gil; Lorenzo Gómez-Aldaraví; José Luis González-Larriba; Bertomeu Massuti; Amalia Velasco; Mariano Provencio; Rafael Rossell; Carlos Camps
Journal:  Clin Transl Oncol       Date:  2011-06       Impact factor: 3.405

3.  Cisplatin and vinorelbine followed by ifosfamide plus epirubicin vs the opposite sequence in advanced unresectable stage III and metastatic stage IV non-small-cell lung cancer: a prospective randomized study of the Southern Italy Oncology Group (GOIM).

Authors:  G Colucci; V Gebbia; D Galetta; F Riccardi; S Cariello; N Gebbia
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

4.  Adjuvant epirubicin followed by cyclophosphamide, methotrexate and fluorouracil (CMF) vs CMF in early breast cancer: results with over 7 years median follow-up from the randomised phase III NEAT/BR9601 trials.

Authors:  H M Earl; L Hiller; J A Dunn; A-L Vallier; S J Bowden; S D Jordan; F Blows; A Munro; S Bathers; R Grieve; D A Spooner; R Agrawal; I Fernando; A M Brunt; S M O'Reilly; S M Crawford; D W Rea; P Simmonds; J L Mansi; A Stanley; K McAdam; L Foster; R C F Leonard; C J Twelves; D Cameron; J M S Bartlett; P Pharoah; E Provenzano; C Caldas; C J Poole
Journal:  Br J Cancer       Date:  2012-09-11       Impact factor: 7.640

5.  Block sequential adriamycin CMF--optimal non-myeloablative chemotherapy for high risk adjuvant breast cancer?

Authors:  D A Cameron; A Anderson; E Toy; T R J Evans; J H Le Vay; I C S Kennedy; R J Grieve; T J Perren; A Jones; J Mansi; J Crown; R C F Leonard
Journal:  Br J Cancer       Date:  2002-12-02       Impact factor: 7.640
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.